Replies to post #340 on Biotech Values

[mba_investor]

Excellent analysis, Dew. Parsing through press releases is harder than it looks but profitable for those who do it as well as you. Your work is appreciated.
Best,
MBA

[T Bishop]

Dew,

I wonder if it is better for GENR if the FDA approves Macugen, thus lowering the bar for Squalamine approval, or if Macugen is NOT approved reducing competition.

-Tom Bishop